INM
InMed Pharmaceuticals Inc.
Key Financials
Net Income
$-12560850
↓ 53.9%
Operating Income
$-7947622
↑ 57.3%
Gross Profit
$1.7M
↑ 55.0%
Total Assets
$3.0M
↓ 80.6%
Revenue
$4.9M
↑ 7.5%
Cash & Equivalents
$11.1M
↑ 68.5%
EPS (Diluted)
$-3.12
↑ 62.7%
Shareholders' Equity
$1.1M
↓ 92.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| EFFECT | 10/1/2026 | View on SEC |
| 424B3 | 10/1/2026 | View on SEC |
| S-4/A | 9/29/2026 | View on SEC |
| 8-K | 9/18/2026 | View on SEC |
| 4 | 9/16/2026 | View on SEC |
| S-4/A | 9/9/2026 | View on SEC |
| 425 | 9/9/2026 | View on SEC |
| 10-K | 9/9/2026 | View on SEC |
| SCHEDULE 13G | 8/14/2026 | View on SEC |
| 425 | 7/22/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | INM |
| Company Name | InMed Pharmaceuticals Inc. |
| CIK | 1728328 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 0630 |
| State of Incorporation | A1 |
| Phone | (604) 669-7207 |